SG11202102478SA - Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor - Google Patents
Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses thereforInfo
- Publication number
- SG11202102478SA SG11202102478SA SG11202102478SA SG11202102478SA SG11202102478SA SG 11202102478S A SG11202102478S A SG 11202102478SA SG 11202102478S A SG11202102478S A SG 11202102478SA SG 11202102478S A SG11202102478S A SG 11202102478SA SG 11202102478S A SG11202102478S A SG 11202102478SA
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- pai
- inhibitor
- administration
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731074P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050849 WO2020056160A1 (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102478SA true SG11202102478SA (en) | 2021-04-29 |
Family
ID=68052024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102478SA SG11202102478SA (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Country Status (14)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2020056191A1 (en) | 2018-09-13 | 2020-03-19 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| CN113155987B (zh) * | 2020-12-28 | 2023-06-06 | 浙江工商大学 | 一种微针贴片及其制备方法、应用 |
| IL327134A (en) | 2023-09-18 | 2026-05-01 | Eirion Therapeutics Inc | Topical formulations and uses of PAI-1 inhibitors |
| WO2026090113A1 (en) * | 2024-10-21 | 2026-04-30 | Versiti Blood Research Institute Foundation, Inc. | Modifying transplantable organs ex vivo with rna lipid nanoparticle perfusion |
| WO2026147911A1 (en) * | 2024-12-30 | 2026-07-09 | Eirion Therapeutics, Inc. | Topical compositions and regimens |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| WO2001051085A1 (en) * | 2000-01-14 | 2001-07-19 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| EP2377532A1 (en) * | 2004-08-18 | 2011-10-19 | Ace ApS | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders |
| PL3144013T3 (pl) | 2005-12-01 | 2019-04-30 | Univ Of Massachusetts Lowell | Nanoemulsje botulinowe |
| EP2015773A4 (en) | 2006-04-27 | 2010-05-05 | Anterios Inc | EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS |
| CN101848702B (zh) | 2006-12-01 | 2013-07-17 | 安特里奥公司 | 两亲实体纳米粒子 |
| WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| MX2010013562A (es) | 2008-06-26 | 2011-02-15 | Anterios Inc | Aplicacion dermica. |
| ES2621849T3 (es) * | 2009-06-26 | 2017-07-05 | Sunny Pharmtech Inc. | Método de tratamiento o mejora de toxicidades mucocutáneas u oculares. |
| ES2720648T3 (es) | 2011-01-24 | 2019-07-23 | Anterios Inc | Composiciones de nanopartículas |
| AU2012209274A1 (en) | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| US9144671B2 (en) | 2011-12-21 | 2015-09-29 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
| WO2020056191A1 (en) * | 2018-09-13 | 2020-03-19 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
-
2019
- 2019-09-12 SG SG11202102478SA patent/SG11202102478SA/en unknown
- 2019-09-12 CN CN201980074633.8A patent/CN113056268A/zh active Pending
- 2019-09-12 KR KR1020217010851A patent/KR102884331B1/ko active Active
- 2019-09-12 US US17/274,948 patent/US20220105068A1/en active Pending
- 2019-09-12 KR KR1020257037244A patent/KR20250163416A/ko active Pending
- 2019-09-12 WO PCT/US2019/050849 patent/WO2020056160A1/en not_active Ceased
- 2019-09-12 ES ES19773718T patent/ES3076115T3/es active Active
- 2019-09-12 DK DK19773718.2T patent/DK3849539T3/da active
- 2019-09-12 AU AU2019338459A patent/AU2019338459B2/en active Active
- 2019-09-12 MX MX2021002995A patent/MX2021002995A/es unknown
- 2019-09-12 EP EP19773718.2A patent/EP3849539B1/en active Active
- 2019-09-12 BR BR112021004542-2A patent/BR112021004542A2/pt unknown
- 2019-09-12 CA CA3112558A patent/CA3112558A1/en active Pending
- 2019-09-12 JP JP2021514401A patent/JP2021535925A/ja active Pending
- 2019-09-12 CN CN202511057022.6A patent/CN120983628A/zh active Pending
-
2021
- 2021-03-11 IL IL281450A patent/IL281450A/en unknown
- 2021-03-12 MX MX2025004193A patent/MX2025004193A/es unknown
-
2024
- 2024-09-12 JP JP2024158484A patent/JP2025011085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021002995A (es) | 2021-07-15 |
| IL281450A (en) | 2021-04-29 |
| US20220105068A1 (en) | 2022-04-07 |
| EP3849539A1 (en) | 2021-07-21 |
| DK3849539T3 (da) | 2026-07-27 |
| ES3076115T3 (en) | 2026-08-12 |
| CN113056268A (zh) | 2021-06-29 |
| MX2025004193A (es) | 2025-05-02 |
| BR112021004542A2 (pt) | 2021-06-08 |
| WO2020056160A1 (en) | 2020-03-19 |
| KR20210057141A (ko) | 2021-05-20 |
| JP2021535925A (ja) | 2021-12-23 |
| JP2025011085A (ja) | 2025-01-23 |
| AU2019338459A1 (en) | 2021-04-08 |
| CN120983628A (zh) | 2025-11-21 |
| KR102884331B1 (ko) | 2025-11-13 |
| KR20250163416A (ko) | 2025-11-20 |
| EP3849539B1 (en) | 2026-07-01 |
| AU2019338459B2 (en) | 2025-07-10 |
| CA3112558A1 (en) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288381A (en) | Tead inhibitors and their uses | |
| IL288384A (en) | Tead inhibitors and their uses | |
| PT4031547T (pt) | Inibidores de calicreína plasmática e utilizações dos mesmos | |
| IL281450A (en) | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor | |
| IL282487B1 (en) | Tyk2 inhibitors and their use | |
| SG11202102479TA (en) | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors | |
| IL279276A (en) | ERK inhibitor and use thereof | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282090B2 (en) | TYK2 inhibitors and their uses | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| IL307187A (en) | MK2 inhibitors and their uses | |
| IL284799A (en) | Tyk2 inhibitors and uses thereof | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL310209A (en) | ROCK2 inhibitors and their uses | |
| ZA202004909B (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| IL291158B2 (en) | Iraq inhibitor and its preparation and use | |
| PT3712147T (pt) | Inibidor de sglts e sua aplicação | |
| PL3657946T3 (pl) | Inhibitor aktywatora plazminogenu-1 (pai-1) i sposób jego zastosowania | |
| IL283706A (en) | Pharmacotherapeutic agents and their use as inhibitors of ubiquitin-specific protease 19 | |
| IL291396A (en) | mll1 inhibitors and anticancer drugs | |
| HK40059344A (en) | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor | |
| HK40058373A (en) | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors | |
| GB201908884D0 (en) | Inhibitors and use | |
| HK40070734A (en) | Tead inhibitors and uses thereof |